Fig. 2.

ALDOA inhibited cell cycle arrest induced by DNA damage. A and B Western blot and qRT-PCR assays confirmed the efficiency in ALDOA-overexpressing PANC-1 and SW1990 cells. C Cell lines were treated with cisplatin (15 µM)/temozolomide (150 µM) to assess the protein level of ALDOA. D Confocal microscopy showed DNA damage (green) and nuclear DNA (blue) in ALDOA-overexpressing or normal PANC-1 and SW1990 cells treated with cisplatin (15 µM)/temozolomide (150 µM). E and H Cell cycle analysis by flow cytometry indicated a marked change in the proportion of cells in G2/M phase in ALDOA-overexpressing or normal PANC-1 and SW1990 cells treated with cisplatin (15 µM)/temozolomide (150 µM). F and G The ALDOA group and the control group respectively were treated with cisplatin (15 µM)/temozolomide (150 µM) to assess colony formation capacity